Robert Tell

Affiliations

Tempus Labs Inc., Chicago, IL 60654, USA.

Réseau de co-auteurs

Nike Beaubier 1 collaboration

Denise Lau 1 collaboration

Jerod R Parsons 1 collaboration

Stephen Bush 1 collaboration

Jason Perera 1 collaboration

Shelly Sorrells 1 collaboration

Timothy Baker 1 collaboration

Alan Chang 1 collaboration

Jackson Michuda 1 collaboration

Catherine Iguartua 1 collaboration

Shelley MacNeil 1 collaboration

Kaanan Shah 1 collaboration

Philip Ellis 1 collaboration

Kimberly Yeatts 1 collaboration

Brett Mahon 1 collaboration

Timothy Taxter 1 collaboration

Martin Bontrager 1 collaboration

Aly Khan 1 collaboration

Robert Huether 1 collaboration

Eric Lefkofsky 1 collaboration

Kevin P White 1 collaboration

Josep Tabernero 1 collaboration

Takayuki Yoshino 1 collaboration

Sebastian Stintzing 1 collaboration

Aimery de Gramont 1 collaboration

Peter Gibbs 1 collaboration

Derek Jonker 1 collaboration

Peter Nygren 1 collaboration

Christos A Papadimitriou 1 collaboration

Gerald W Prager 1 collaboration

Roger Tell 1 collaboration

Heinz-Josef Lenz 1 collaboration

G Carlsson 1 collaboration

A Koumarianou 1 collaboration

T K Guren 1 collaboration

J Haux 1 collaboration

P Katsaounis 1 collaboration

N Kentepozidis 1 collaboration

P Pfeiffer 1 collaboration

M Brændengen 1 collaboration

D Mavroudis 1 collaboration

H Taflin 1 collaboration

L Skintemo 1 collaboration

R Tell 1 collaboration

C Papadimitriou 1 collaboration

Robert Tell

Affiliations

Publications (3)

Clinical validation of the tempus xT next-generation targeted oncology sequencing assay.

A Randomized Phase III Study of Arfolitixorin Versus Leucovorin with 5-Fluorouracil, Oxaliplatin and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.

A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer.

Réseau de co-auteurs